Kuanoniamine A
Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma.
For research use only. We do not sell to patients.
- CAS No.: 133401-10-2
- Formula: C16H7N3OS
- Molecular Weight:289.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
Kuanoniamine A (48 h) potently inhibits the growth of MCF-7, MDA-MB-231, NCI-H460, SF-268, UACC-62, and MRC-5 cells with GI50 values ranging from 0.12 to 4.67 μM after 48 h of continuous exposure[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) potently inhibits DNA synthesis in MCF-7 cells, with a concentration-dependent effect that reduces thymidine incorporation by over 60% at 0.08 μM across 6, 12, 24, and 48 h exposure times[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces MCF-7 cell viability in a time-dependent manner, decreasing viability to 70% at 0.04 μM after 6 h exposure, with more severe reductions after 24 and 48 h[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces cellular protein content in MCF-7 cells in a time-dependent manner, with effects mirroring its impact on cell viability measured by the MTT assay[1].
Kuanoniamine A (0.34 μM; 24 h) reduces the proportion of MCF-7 cells in G2/M phase, accumulates cells in G1 phase, and decreases the S phase fraction relative to untreated control cells[1].
Kuanoniamine A (0.5-1.0 μM; 24 h) increases the number of apoptotic MCF-7 cells relative to untreated control cells[1].
Kuanoniamine A (0.5-2.5 μM; 24 h) reduces MCF-7 cell viability to ≥70% at 0.5 and 1.0 μM after 24 h, while 2.5 μM drastically reduces viability to 35.7%[1].
Kuanoniamine A (0.12-86.51 μM; 96 h) potently inhibits PHA-induced proliferation of human lymphocytes with an IC50 of 1.50 μM after 96 h of continuous exposure[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7
-
Concentration:0.34 μM
-
Incubation Time:24 h
-
Result:Caused an extensive reduction in the fraction of cells in G2/M phase (5.71% vs.
12.17% in control), a corresponding accumulation of cells in G1 phase (81.41% vs.
70.04% in control), and a reduction in the S phase fraction (12.88% vs.
17.79% in control).
-
Cell Line:MCF-7
-
Concentration:0.5 and 1.0 μM
-
Incubation Time:24 h
-
Result:Increased the number of apoptotic cells; 0.5 μM treatment resulted in 6.19% apoptotic cells, and 1.0 μM treatment resulted in 7.2% apoptotic cells, compared to 1.41% in untreated control cells.
-
Cell Line:MCF-7
-
Concentration:0.5, 1 and 2.5 μM
-
Incubation Time:24 h
-
Result:Moderately reduced viability at 0.5 and 1.0 μM (≥70% viable cells), while 2.5 μM caused a drastic decrease in viability to 35.7%.
Chemical Information
-
CAS No. 133401-10-2
-
Molecular Weight 289.31
-
Formula C16H7N3OS
-
SMILES
O=C1C2=NC=3C=CC=CC3C=4C=CN=C(C=5N=CSC15)C24
-
Structure Classification
-
Initial Source
Oceanapia sagittaria
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)